Editas Medicine Posts Q1 Loss of $25M; Preclinical EDIT-401 Shows >90% LDL-C Drop
Editas recorded Q1 net loss of $25M (¢0.26/share) versus $76.1M year ago, with $2.8M revenue and $123.6M cash funding operations into Q3 2027. EDIT-401 preclinical data showed over 90% mean LDL-C reduction and remains on track for first human proof-of-concept by year-end 2026.
1. Financial Results Q1 2026
Editas Medicine reported a Q1 net loss of $25.0 million, or $0.26 per share, compared to a $76.1 million, or $0.92 per share, loss in Q1 2025. Collaboration revenue fell to $2.8 million, below analyst forecasts of $8.6 million; R&D expenses declined by $9.0 million to $17.6 million and G&A expenses decreased by $3.1 million to $10.2 million, with no restructuring charges this quarter versus $40.9 million a year earlier.
2. Pipeline Advances
The company advanced its lead candidate, EDIT-401, generating preclinical results showing over 90% mean LDL-C reduction and meaningful decreases in Lp(a) and ApoB in non-human primates. Editas plans data presentations at upcoming ASGCT, TIDES USA and EAS meetings and expects to initiate a first-in-human trial in heterozygous familial hypercholesterolemia patients by year-end 2026, aiming for dose-finding topline results in 2027.
3. Cash Runway and Intellectual Property
Cash and cash equivalents totaled $123.6 million at March 31, 2026 versus $146.6 million at December 31, 2025, providing a runway into Q3 2027. The U.S. Patent and Trademark Office reaffirmed the patent interference decision favoring the Broad Institute in CRISPR/Cas9 patents, with CVC retaining the right to appeal.